Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Association of Serum MMP-9 Level and Lung Function in New Pulmonary Tuberculosis Case

Author(s): Daniel Maranatha* and Devi Ambarwati

Volume 18, Issue 2, 2022

Published on: 31 May, 2022

Page: [115 - 120] Pages: 6

DOI: 10.2174/1573398X18666220407084457

Price: $65

Abstract

Background: Histopathological abnormalities of pulmonary tuberculosis (TB) include caseous granuloma formation, tissue damage, and cavity formation, all of which could lead to permanent changes in the pulmonary anatomy. In pulmonary TB, an increase in serum Matrix Metalloproteinase (MMP)-9 correlates with disease severity and worse prognosis. This study aims to analyze the association between serum MMP-9 levels and the values of FVC, FEV1, and FEV1/FVC.

Methods: A cross-sectional study involving patients with pulmonary tuberculosis was conducted at the Tuberculosis Outpatient Clinic, Dr. Soetomo Academic Hospital, Surabaya, Indonesia. Spirometry and serum MMP-9 levels were examined in new pulmonary TB patients prior to antituberculosis therapy. The relationship between serum MMP-9 levels and results of spirometry examination was then analyzed.

Results: There were 44 new pulmonary TB cases with a mean age of 37.90 ± 15.15 years. The patients who experienced symptoms in <1 month were 20.5%, ≥ 1 month were 59.1%, and ≥ 2 months were 20.4%. The mean MMP-9 serum level was 11.27 ± 5.47 ng/ml. Spirometry results were: FVC 1.83 ± 0.69 L, FVC predicted 56.24 ± 18.74%, FEV1 1.71 ± 0.72 L/sec, FEV1 predicted 60.85 ± 21.30%, and FEV1/FVC 104.16 ± 17.45%. In pulmonary TB patients with symptoms experienced in <1 month, a significant relationship between MMP-9 and FVC levels was found with r = -0.839 (p = 0.005).

Conclusion: There is a correlation between serum MMP-9 level and restrictive pulmonary impairment in new pulmonary TB cases with symptoms experienced in <1 month.

Keywords: Tuberculosis, pulmonary, matrix metalloproteinases, spirometry, extracellular matrix, respiratory function tests.

« Previous Next »
Graphical Abstract

[1]
Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary tuberculosis treated with directly observed therapy: Serial changes in lung structure and function. Chest 1998; 113(4): 933-43.
[http://dx.doi.org/10.1378/chest.113.4.933] [PMID: 9554628]
[2]
Gaensler EA, Lindgren I. Chronic bronchitis as an etiologic factor in obstructive emphysema; preliminary report. Am Rev Respir Dis 1959; 80(1, Part 2): 185-93.
[PMID: 13670424]
[3]
Plit ML, Anderson R, Van Rensburg CEJ, et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998; 12(2): 351-6.
[http://dx.doi.org/10.1183/09031936.98.12020351] [PMID: 9727784]
[4]
Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GAW. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005; 192(7): 1201-9.
[http://dx.doi.org/10.1086/444545] [PMID: 16136463]
[5]
Sabir N, Hussain T, Mangi MH, Zhao D, Zhou X. Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif 2019; 52(4): e12649.
[http://dx.doi.org/10.1111/cpr.12649] [PMID: 31199047]
[6]
Sheen P, O’Kane CM, Chaudhary K, et al. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J 2009; 33(1): 134-41.
[http://dx.doi.org/10.1183/09031936.00127807] [PMID: 18715875]
[7]
Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis 2002; 6(8): 713-9.
[PMID: 12150484]
[8]
Singh S, Kubler A, Singh UK, et al. Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. Antimicrob Agents Chemother 2014; 58(8): 4657-65.
[http://dx.doi.org/10.1128/AAC.02141-13] [PMID: 24890593]
[9]
Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: From epidemiology to pathophysiology. Eur Respir Rev 2018; 27(147): 170077.
[http://dx.doi.org/10.1183/16000617.0077-2017] [PMID: 29491034]
[10]
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26(5): 948-68.
[http://dx.doi.org/10.1183/09031936.05.00035205] [PMID: 16264058]
[11]
Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4(8): 617-29.
[http://dx.doi.org/10.1038/nri1418] [PMID: 15286728]
[12]
Quiding-Järbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun 2001; 69(9): 5661-70.
[http://dx.doi.org/10.1128/IAI.69.9.5661-5670.2001] [PMID: 11500442]
[13]
Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS. Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 2001; 166(6): 4223-30.
[http://dx.doi.org/10.4049/jimmunol.166.6.4223] [PMID: 11238675]
[14]
Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, Rom WN. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996; 51(3): 306-11.
[http://dx.doi.org/10.1136/thx.51.3.306] [PMID: 8779137]
[15]
Taylor JL, Hattle JM, Dreitz SA, et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tu-berculosis infection. Infect Immun 2006; 74(11): 6135-44.
[http://dx.doi.org/10.1128/IAI.02048-05] [PMID: 16982845]
[16]
Kathamuthu GR, Kumar NP, Moideen K, et al. Matrix metalloproteinase and tissue inhibitors of metalloproteinases are potential bi-omarkers of pulmonary and extra-pulmonary tuberculosis. Front Immunol 2020; 11: 419.
[http://dx.doi.org/10.3389/fimmu.2020.00419] [PMID: 32218787]
[17]
Le Y, Cao W, Zhou L, et al. Infection of Mycobacterium tuberculosis promotes both M1/M2 polarization and MMP-production in cigarette smoke-exposed macrophage. Front Immunol 2020; 11: 1902.
[http://dx.doi.org/10.3389/fimmu.2020.01902] [PMID: 32973788]
[18]
Radovic M, Ristic L, Ciric Z, et al. Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis - limitations for the underlying COPD detection. Int J Chron Obstruct Pulmon Dis 2016; 11: 1307-16.
[http://dx.doi.org/10.2147/COPD.S106875] [PMID: 27366058]
[19]
Pradipta SG, Suryadinata H. Setiawan. Pulmonary function of tuberculosis patients in medication at Dr. Hasan Sadikin general hospital Bandung 2013-2014. AMJ 2017; 4: 402-6.
[20]
Rhee CK, Yoo KH, Lee JH, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis 2013; 17(1): 67-75.
[http://dx.doi.org/10.5588/ijtld.12.0351] [PMID: 23232006]
[21]
Azikin W, Laompo A, Albar H, Daud D. Matrix metalloproteinase-9 (MMP-9) level in tuberculosis exposed and infected children. Am J Health Res 2017; 5: 7-10.
[22]
Salgame P. MMPs in tuberculosis: Granuloma creators and tissue destroyers. J Clin Invest 2011; 121(5): 1686-8.
[http://dx.doi.org/10.1172/JCI57423] [PMID: 21519148]
[23]
Li Y, Wang Y, Liu X. The role of airway epithelial cells in response to mycobacterium infection. Clin Dev Immunol 2012; 2012: 791392.
[http://dx.doi.org/10.1155/2012/791392]
[24]
Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010; 327(5964): 466-9.
[http://dx.doi.org/10.1126/science.1179663] [PMID: 20007864]

Rights & Permissions Print Cite
Article Metrics
12
© 2024 Bentham Science Publishers | Privacy Policy